4dmt announces accelerated 4d-150 phase 3 development in wet amd and streamlined organization to drive late-stage execution

Emeryville, calif., july 02, 2025 (globe newswire) -- 4d molecular therapeutics (nasdaq: fdmt, 4dmt or the company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced the acceleration of the 4d-150 4front phase 3 program in wet age-related macular degeneration (wet amd). the company also has streamlined operations to offset additional expenses expected based on the accelerated timelines for the 4front clinical trials and bla preparation, which supports the company's cash runway into 2028, as previously guided. the transition reflects the company's focus on its late-stage pipeline, a strategy previously announced in january 2025.
AMD Ratings Summary
AMD Quant Ranking